MediPharm Labs Competitors

MediPharm Labs (OTCMKTS:MEDIF) and Abacus Health Products (OTCMKTS:ABAHF) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, institutional ownership and valuation.

Earnings & Valuation

This table compares MediPharm Labs and Abacus Health Products' revenue, earnings per share and valuation.

Analyst Ratings

This is a breakdown of recent recommendations for MediPharm Labs and Abacus Health Products, as reported by MarketBeat.

MediPharm Labs currently has a consensus target price of $1.3750, indicating a potential upside of 266.28%. Given MediPharm Labs' higher possible upside, equities research analysts plainly believe MediPharm Labs is more favorable than Abacus Health Products.

Profitability

This table compares MediPharm Labs and Abacus Health Products' net margins, return on equity and return on assets.

Summary

MediPharm Labs beats Abacus Health Products on 2 of the 2 factors compared between the two stocks.

Acreage (OTCMKTS:ACRGF) and MediPharm Labs (OTCMKTS:MEDIF) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, earnings, institutional ownership and risk.

Earnings and Valuation

This table compares Acreage and MediPharm Labs' top-line revenue, earnings per share (EPS) and valuation.

Analyst Recommendations

This is a breakdown of recent ratings for Acreage and MediPharm Labs, as reported by MarketBeat.

Acreage presently has a consensus target price of $8.4333, indicating a potential upside of 204.45%. MediPharm Labs has a consensus target price of $1.3750, indicating a potential upside of 266.28%. Given MediPharm Labs' higher possible upside, analysts clearly believe MediPharm Labs is more favorable than Acreage.

Profitability

This table compares Acreage and MediPharm Labs' net margins, return on equity and return on assets.

Summary

MediPharm Labs beats Acreage on 2 of the 3 factors compared between the two stocks.

Applied Biosciences (OTCMKTS:APPB) and MediPharm Labs (OTCMKTS:MEDIF) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, earnings, institutional ownership and risk.

Earnings and Valuation

This table compares Applied Biosciences and MediPharm Labs' top-line revenue, earnings per share (EPS) and valuation.

Analyst Recommendations

This is a breakdown of recent ratings for Applied Biosciences and MediPharm Labs, as reported by MarketBeat.

MediPharm Labs has a consensus target price of $1.3750, indicating a potential upside of 266.28%. Given MediPharm Labs' higher possible upside, analysts clearly believe MediPharm Labs is more favorable than Applied Biosciences.

Profitability

This table compares Applied Biosciences and MediPharm Labs' net margins, return on equity and return on assets.

Summary

MediPharm Labs beats Applied Biosciences on 2 of the 2 factors compared between the two stocks.

Ayr Strategies (OTCMKTS:AYRSF) and MediPharm Labs (OTCMKTS:MEDIF) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, earnings, institutional ownership and risk.

Earnings and Valuation

This table compares Ayr Strategies and MediPharm Labs' top-line revenue, earnings per share (EPS) and valuation.

Analyst Recommendations

This is a breakdown of recent ratings for Ayr Strategies and MediPharm Labs, as reported by MarketBeat.

Ayr Strategies presently has a consensus target price of $34.8571, indicating a potential upside of 63.96%. MediPharm Labs has a consensus target price of $1.3750, indicating a potential upside of 266.28%. Given MediPharm Labs' higher possible upside, analysts clearly believe MediPharm Labs is more favorable than Ayr Strategies.

Profitability

This table compares Ayr Strategies and MediPharm Labs' net margins, return on equity and return on assets.

Summary

Ayr Strategies beats MediPharm Labs on 2 of the 3 factors compared between the two stocks.

Can B (NASDAQ:CANB) and MediPharm Labs (OTCMKTS:MEDIF) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, earnings, institutional ownership and risk.

Profitability

This table compares Can B and MediPharm Labs' net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent ratings for Can B and MediPharm Labs, as reported by MarketBeat.

MediPharm Labs has a consensus target price of $1.3750, indicating a potential upside of 266.28%. Given MediPharm Labs' higher possible upside, analysts clearly believe MediPharm Labs is more favorable than Can B.

Earnings and Valuation

This table compares Can B and MediPharm Labs' top-line revenue, earnings per share (EPS) and valuation.

Summary

MediPharm Labs beats Can B on 2 of the 2 factors compared between the two stocks.

Cansortium (OTCMKTS:CNTMF) and MediPharm Labs (OTCMKTS:MEDIF) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, dividends and institutional ownership.

Profitability

This table compares Cansortium and MediPharm Labs' net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of current recommendations and price targets for Cansortium and MediPharm Labs, as provided by MarketBeat.com.

Cansortium currently has a consensus target price of $1.20, suggesting a potential upside of 18.81%. MediPharm Labs has a consensus target price of $1.3750, suggesting a potential upside of 266.28%. Given MediPharm Labs' higher possible upside, analysts plainly believe MediPharm Labs is more favorable than Cansortium.

Earnings and Valuation

This table compares Cansortium and MediPharm Labs' top-line revenue, earnings per share and valuation.

Summary

MediPharm Labs beats Cansortium on 2 of the 3 factors compared between the two stocks.